Wegovy pill for women has reached a new clinical milestone following the release of comprehensive data from the 2026 European Congress on Obesity (ECO) in Istanbul. Novo Nordisk announced that semaglutide (2.4 mg and the new 7.2 mg high-dose) provides not only significant weight management but also critical protection against comorbid conditions like migraines and depression, regardless of a woman’s reproductive life stage.
Understanding the Impact of Wegovy for Women Across Menopause Stages
As women transition through different hormonal phases, weight management becomes increasingly difficult due to metabolic shifts. The new analysis specifically examined the efficacy of Wegovy for women across premenopausal, perimenopausal, and postmenopausal groups.
The findings, derived from the STEP UP and SELECT trials, indicate that the medication effectively addresses the “menopause weight gap.” For years, hormonal changes during menopause have been a primary driver of visceral fat accumulation. However, the data confirms that Wegovy for women targets this specific fat, significantly reducing waist circumference and lowering the risk of heart attacks and strokes.
Neurological and Mental Health Breakthroughs
One of the most striking revelations in the report is the reduction in non-metabolic conditions. Women treated with Wegovy for women experienced a 42–45% lower risk of migraines compared to those on menopausal hormone therapy (MHT) alone. Additionally, the risk of depression was reduced by 25%, highlighting the drug’s potential role in holistic female healthcare.
Weight Loss Efficacy by Menopausal Status (STEP UP Trial)
| Patient Group | Mean Weight Loss (%) | Exceptional Responders (≥25% Loss) | Dose |
| Premenopausal Women | 22.6% | 41.4% | 7.2 mg |
| Perimenopausal Women | 21.3% | 38.9% | 7.2 mg |
| Postmenopausal Women | 20.8% | 36.5% | 7.2 mg |
| Placebo Control | 1.8% | 2.1% | N/A |
Risk Reduction in Secondary Health Outcomes
| Condition | Risk Reduction Percentage | Comparison Group |
| Migraine Frequency | 42% – 45% | Menopausal Hormone Therapy Alone |
| Depression Symptoms | 25% | Standard Care / MHT |
| Cardiovascular Events | 42% (Perimenopausal) | Placebo |
| Visceral Fat (Waist Cir.) | -19.4 cm (Average) | Baseline |
The Future of Obesity Care for Women
We are very pleased by the clinical profile of Wegovy for women.
Mette Thomsen, Group Vice President at Novo Nordisk
By combining weight loss with significant reductions in daily burdens like migraines, Novo Nordisk is positioning semaglutide as more than just a weight-loss tool, but as a foundational therapy for women’s health.
